Comparison between real-time quantitative PCR detection of HER2 mRNA copy number in peripheral blood and ELISA of serum HER2 protein for determining HER2 status in breast cancer patients

Cellular Oncology

Volumn 31, Issue 3, 2009, Pages 203-211

  Savino, Maria ^a   Parrella, Paola ^a   Copetti, Massimiliano ^a   Barbano, Raffaela ^a   Murgo, Roberto ^a   Fazio, Vito Michele ^a   Valori, Vanna Maria ^a   Carella, Massimo ^a   Garrubba, Maria ^a   Santini, Stefano Angelo ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Breast cancer; EIA; HER2; IHC; QPCR; RT PCR

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; PLASMA PROTEIN; RNA 28S;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENE AND NUCLEIC ACID PARAMETERS; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE NEU; ONCOGENE NEU MESSENGER RNA COPY NUMBER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; ROC CURVE; SENSITIVITY AND SPECIFICITY; SERUM;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE DOSAGE; HUMANS; MIDDLE AGED; POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; RNA, MESSENGER;

EID: 67650224300     PISSN: 15705870     EISSN: None     Source Type: Journal    
DOI: 10.1155/2009/206068     Document Type: Article

References (22)

1. D. Bafaloukos, Neoadjuvant therapy in breast cancer, Ann. Oncol. 16(Suppl. 2) (2005), ii174-ii181.
2. I. Bieche, P. Onody, I. Laurendeau, M. Olivi, D. Vidaud, R. Lid- ereau and M. Vidaud, Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications, Clin. Chem. 45(1999), 1148-1156.
3. A. Citri and Y. Yarden, EGF-ERBB signalling: towards the systems level, Nat. Rev. Mol. Cell. Biol. 7(2006), 505-516.
4. V. D'Alessandro, L.A. Muscarella, M. Copetti, L. Zelante, M. Carella and G. Vendemiale, Molecular detection of neuron- specific ELAV-like-positive cells in the peripheral blood of patients with small-cell lung cancer, Cell. Oncol. 30(2008), 291-297.
5. V. D'Alessandro, L.A. Muscarella, M. Copetti, L. Zelante, M. Carella, G. Vendemiale, M. Savino, M. Garrubba, P. Par- rella, F. Baorda, M. Copetti, R. Murgo et al., Development of real-time quantitative reverse transcription-PCR for Her2 detection in peripheral blood from patients with breast cancer, Clin. Chim. Acta 384(2007), 52-56.
6. K. Dheda, J.F. Huggett, S.A. Bustin, M.A. Johnson, G. Rook and A. Zumla, Validation of housekeeping genes for normalizing RNA expression in real-time PCR, BioTechniques 37(2004), 112-119.
7. P.P. Di Fiore, J.H. Pierce, T.P. Fleming, R. Hazan, A. Ullrich, C.R. King et al., Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells, Cell 51(1987), 1063-1070.
8. P. Dinh, E. de Azambuja and M.J. Piccart-Gebhart, Trastuzumab for early breast cancer: current status and future directions, Clin. Adv. Hematol. Oncol. 5(2007), 707-717.
9. C.M. Ellis, M.J. Dyson, T.J. Stephenson and E.L. Maltby,HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situhybridisation using manual and automated quantitative image analysis scoring techniques, J. Clin. Pathol. 58(2005), 710-714.
10. G. Ferretti, A. Felici, P. Papaldo, A. Fabi and F. Cognetti, HER2/neu role in breast cancer: from a prognostic foe to a predictive friend, Curr. Opin. Obstet. Gynecol. 19(2007), 56-62.
11. C.A. Heid, J. Stevens, K.J. Livak and P.M. Williams, Real time quantitative PCR, Genome Res. 6(1996), 986-994.
12. E.A. Janssen, P.J. van Diest, H. Soiland et al., Success predictors of adjuvant chemotherapy in node-negative breast cancer patients under 55 years, Cell. Oncol. 28(5/6) (2006), 295-303.
13. U. Lehmann, S. Glockner, W. Kleeberger, H.F. von Wasielewski and H. Kreipe, Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction, Am. J. Pathol. 156(2000), 1855-1864.
14. M.B. Lyng, A.V. Laenkholm, N. Pallisgaard et al., Intratumor genetic heterogeneity of breast carcinomas as determined by fine needle aspiration and TaqMan low density array, Cell. Oncol. 29(2007), 361-372.
15. E. Moerland, R.L. van Hezik, T.C. van der Aa, M.W. van Beek and A.J. van den Brule, Detection of HER2 amplification in breast carcinomas: comparison of multiplex ligation-dependent probe amplification (MLPA) and fluorescence in situhybridization (FISH) combined with automated spot counting, Cell. Oncol. 28(4) (2006), 151-159.
16. R. Nishimura, Y. Okumura and N. Arima, Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival, Breast Cancer 15(2008), 57-64.
17. F.P. O'Malley, R. Parkes, E. Latta, S. Tjan, T. Zadro, R. Mueller et al., Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry, Am. J. Clin. Pathol. 115(2001), 504-511.
18. P. Parrella, D. Sidransky and S.L. Merbs, Allelotype of posterior uveal melanoma: implications for a bifurcated tumor progression pathway, Cancer Res. 59(1999), 3032-3037.
19. G. Pauletti, S. Dandekar, H. Rong, L. Ramos, H. Peng, R. Se- shadri and D.J. Slamon, Assessment of methods for tissue- based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situhybridization and immunohistochemistry, J. Clin. Oncol. 18(2000), 3651-3664.
20. M.J. Piccart-Gebhart, Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn, Eur. J. Cancer 42(2006), 1715-1719.
21. K.I. Pritchard, L.E. Shepherd, F.P. O'Malley, I.L. Andrulis, D. Tu, V.H. Bramwell and M.N. Levine, HER2 and responsiveness of breast cancer to adjuvant chemotherapy, N. Engl. J. Med. 354(2006), 2103-2111.
22. F. Revillion, V. Lhotellier, L. Hornez, J. Bonneterre and J.P. Peyrat, ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis, Ann. Oncol. 19(2008), 73-80.